Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celularity IncCELU · Entity 7145 | EVP, Clinical Development | September 13, 2021 | September 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celularity Inc
Report date September 13, 2021 · Filed September 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 · Expires 2031-09-13 | Direct | 125,000 |
Reported balance
After 2021-09-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-13 · Grant · Acquired 125,000 · Balance 125,000 F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, September 13, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and 1/48 of the total number of shares each month thereafter over the following three years, such that the options will be 100% vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, September 13, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and 1/48 of the total number of shares each month thereafter over the following three years, such that the options will be 100% vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2021 Filed Sep 15, 2021 18:50 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $6.87 | $0.00 |
DisclosureSEC source: 0001213900-21-048290 · ownership.xml · derivative · entry 1 Mirakhur Beloo · CIK 0001883292 · EVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Class A Common Stock · 125,000 shares Expires 2031-09-13 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, September 13, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and 1/48 of the total number of shares each month thereafter over the following three years, such that the options will be 100% vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.